Is retatrutide available in Australia for weight loss?

No. Retatrutide has not been approved by the Therapeutic Goods Administration (TGA) for any use in Australia outside of clinical trial settings. It is not available on the PBS or as an approved private prescription. Products sold or advertised as retatrutide in Australia are unapproved goods under the Therapeutic Goods Act 1989 and may contain entirely different substances — including unlabelled doses of approved drugs at dangerous concentrations. Patients should be advised that purchasing these products online or from compounders outside clinical trial protocols is unsafe and illegal.

What should a GP do if a patient is using peptides for weight loss?

Take a full medication history that explicitly asks about peptides, injections, or supplements purchased online. Document what the patient is taking or has taken. Advise them of the risks: unknown ingredients, no sterility guarantee, unpredictable dosing, and severe adverse events including oesophageal tear, aspiration, and systemic toxicity. Explore whether approved weight management pharmacotherapy — including compounded or branded semaglutide through TGA-approved channels — is appropriate for their clinical picture. If they have already taken an unlicensed peptide and report gastrointestinal symptoms, take these seriously: forceful vomiting after peptide use can indicate dangerously supratherapeutic semaglutide exposure.

Unlicensed weight-loss peptides just caused a torn oesophagus

Patients have been purchasing unlicensed peptides for weight loss in Australia for months. General practice has been playing catch-up — fielding questions about products GPs cannot prescribe, cannot examine, and in many cases cannot even identify. The system of regulation has not kept pace with the speed of the online market.

A recent case involving an oesophageal tear following unlicensed retatrutide use is a sentinel event that changes the risk framing for these conversations. This is no longer a story about regulatory arbitrage and uncertain quality. It is now a story about a patient who nearly died.

What happened

A person using a product labelled as retatrutide for weight loss developed uncontrollable vomiting, followed by a torn oesophagus requiring hospitalisation. An oesophageal tear — also known as Boerhaave syndrome — is described as almost universally fatal without prompt treatment.

Testing of the product revealed it did not contain what it claimed. The substance labelled as retatrutide actually contained semaglutide at approximately eight times the normal therapeutic dose. That concentration produced severe gastrointestinal effects — extreme nausea and forceful vomiting — consistent with massive semaglutide overdose.

The mechanism is well understood. Semaglutide works partly through slowing gastric emptying and acting on GLP-1 receptors in the gut and brain. At supratherapeutic doses, those effects become dangerous. Forceful vomiting can create enough intraesophageal pressure to rupture the wall of the oesophagus — a catastrophic complication that requires emergency surgical management.

The TGA has issued a warning: retatrutide must not be used outside approved clinical trial settings in Australia.

The context your patients are operating in

The appeal of unlicensed peptides to patients is not irrational in the way that, say, homeopathic self-treatment for appendicitis is irrational. The clinical need is real. Approved GLP-1 receptor agonists for weight management — semaglutide and tirzepatide — have been in persistent short supply in Australia. Access through the PBS has been gated and contested. For patients who do not meet the threshold for PBS-subsidised treatment, the private out-of-pocket cost is significant.

Retatrutide, a triple hormone receptor agonist (GLP-1/GIP/glucagon) currently in phase-three trials internationally, has been marketed as the “next generation” of GLP-1 therapy with a better side-effect profile and greater efficacy. The marketing is ahead of the evidence, which is not unusual for compounds in late-phase development. But the gap between “marketed online” and “regulated and tested” is where the danger lives.

Use of retatrutide among Australian patients has increased noticeably over the preceding three to six months, according to clinicians. That means GPs are already seeing these patients, even if the patients are not volunteering this information.

Both sides of this

The case for vigilance is clear. Unlicensed peptides contain unknown ingredients. They carry no sterility guarantee. The dosing is unpredictable. And as this case shows, what is labelled as one compound may actually be another — at a concentration that could kill.

The case for taking patients seriously is equally clear. Dismissing the clinical need that drives people toward unlicensed peptides does not make the need go away. It makes the person less likely to tell their GP they are using something, which means GPs are less able to intervene early when something goes wrong.

A better outcome in this case would have been a patient who told their GP what they were taking before an emergency presentation. That conversation is only possible in a clinical relationship where the patient trusts they will be heard rather than lectured.

2 cents this week

Ask about peptides and injections explicitly. Standard medication history questions often miss non-prescribed injectables. A direct, non-judgmental question — “Are you taking any injections or supplements for weight management that weren’t prescribed by your doctor?” — opens the door.

Take gastrointestinal symptoms after peptide use seriously. Forceful or uncontrollable vomiting in someone who has used unlicensed peptides is a potential medical emergency, not a simple side effect to manage at home. Chest pain, back pain, or odynophagia following severe vomiting in this context warrants urgent assessment for oesophageal injury.

Explore the underlying clinical need. Patients are not using unlicensed peptides because they enjoy black-market pharmacology. They are using them because weight management through approved channels has been inaccessible, expensive, or both. If an approved pathway is available — including compounded semaglutide through TGA-approved compounders — that is a conversation worth having in the consulting room.

Document what you discuss. If a patient continues using an unlicensed product after you have advised them of the risks, document the conversation. Clear clinical documentation protects both the patient and the practitioner.

The oesophageal tear case is a sentinel event. It will not be the last serious adverse event from unlicensed peptide use in Australia. But it does crystallise the risk in a way that changes how these conversations should be framed — in general practice, and with patients directly.

Verdict: yes — the TGA warning is current and the clinical risk is real.

Sources cited

Fresh warning after peptide user suffers torn oesophagus — ABC News, 14 September 2026